Aquestive Therapeutics
Aquestive is a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies.
Investor website: https://aquestive.com/
We don’t have processed documents for Aquestive Therapeutics yet, so the AI assistant isn’t available on this page.
About
Aquestive is a pharmaceutical company advancing medicines to bring meaningful improvement to patients' lives through innovative science and delivery technologies. With proprietary technologies like PharmFilm® and AdrenaVerse™, we’re advancing patient-friendly alternatives to inconvenient or invasive therapies, including investigational treatments for anaphylaxis and potentially alopecia areata. Our expertise spans the full product lifecycle, from formulation to commercialization, with four commercialized products marketed by our licensees in the U.S. and around the world. We have the expertise to manufacture and package a wide range of pharmaceutical products, including oral films, creams, and lotions, for our contract licensees and customers. Since the inception of the Company, we have been committed to our purpose: developing pharmaceutical products to deliver complex molecules through administrations that are alternatives to invasive and inconvenient standard of care therapies.
Verified company data
- Cash position
- $110.7 million
- Shares outstanding
- 98,871,369
- Projects
- ["Anaphylm™ (dibutepinephrine) sublingual film\n\nAnaphylm™ (dibutepinephrine) sublingual film is the first orally delivered film formulation of epinephrine in clinical development for the emergency treatment of severe allergic reactions, including anaphylaxis.\n\nDeveloped using both of Aquestive's core technologies (PharmFilm® and AdrenaVerse™), Anaphylm™ is designed to deliver rapid, effective treatment without the need for injection. Compact, portable, and easy to administer, Anaphylm™ begins to dissolve on contact and requires no water or swallowing—ideal for real-world emergencies.\n\n\n\nAbout anaphylaxis\n\nAnaphylaxis is a life-threatening allergic reaction that can occur within minutes of exposure to triggers such as foods, medications, or insect stings. It can cause symptoms ranging from rash and swelling to airway obstruction, loss of consciousness, or even death. The standard-of-care treatment—epinephrine injection—works to reverse these effects, but timely administration is critical for survival.\n\nLooking for clinical trial data?\n\nView the latest posters, presentations, and data with our clinical trial portal.\n\n[Visit the portal](https://data.aquestive.com/ \"Visit the portal\")"]
- Leadership
- Rich Daly (Director, Biopharmaceutical executive with over 30 years of leadership experience in global pharmaceutical companies and biotechnology organizations. Currently serves as President, Global Rare Disease at Angelini Pharma S.p.A.), Marco Taglietti, M.D. (Director, Chief Executive Officer of NanoNewron, with extensive experience in the pharmaceutical and biotechnology industry.), Timothy E. Morris (Director, Chief Operating Officer of Humanetics Corporation), Julie Krop, M.D. (Director, Chief Medical Officer of DiaMedica Therapeutics, Inc.), Thomas A. Zalewski (not discovered), John Oppenheimer, M.D. (not discovered), Jay Lieberman, M.D. (not discovered), Ruchi Gupta, M.D. MPH (not discovered), Matthew Greenhawt, M.D. (not discovered), David BK Golden, M.D. (not discovered), David M. Fleischer, M.D. (not discovered), Carlos Camargo, M.D. (not discovered), David Bernstein, M.D. (not discovered)
Verified data last updated: